Metamark and Janssen will work together to validate some of those gene targets. Once targets are chosen for further pursuit, Janssen will be responsible for the development and commercialization of therapies meant to inhibit those genes.

Under the agreement, Metamark will receive an undisclosed up-front payment and will be eligible for up to $365 million in milestone payments.